- Charles River 1st quarter revenue beat estimates at $1.01 billion, marking a decrease of 1.7% compared to the previous year.
- Research Models and Services revenue increased by 11% compared to the previous year, reaching $220.9 million. This surpassed the estimate of $202.9 million.
- Discovery and Safety Assessment revenue fell short of estimates at $605.5 million, down 8.6% year on year. The estimate was $619.5 million.
- Manufacturing Solutions Revenue saw an increase of 11% on a year-on-year basis, reaching $185.2 million. This is above the estimated $171.1 million.
- The company’s adjusted earnings per share (EPS) were $2.27.
- Out of the analysts covering Charles River, 10 recommended buying the company’s shares, 7 recommended holding them, while none recommended selling them.
A look at Charles River Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Charles River Laboratories is poised for long-term growth and success. With a strong emphasis on growth and momentum, the company is positioned well for future expansion and innovation in the industry. While its value and dividend scores are moderate, the high scores in growth and momentum indicate a positive outlook for investors looking towards the future.
Charles River Laboratories International, Inc. is a key player in providing research tools and support services for drug discovery and development. Specializing in animal research models, the company caters to a wide range of clients including pharmaceutical and biotechnology companies, hospitals, and academic institutions. With a focus on innovation and growth, Charles River Laboratories is positioned to continue its contribution to advancing drug development and therapies in the foreseeable future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
